Evidence map›Paper›PMID 41795057›Full record

ReviewDrug delivery and translational research2026

Clinical translation and landscape of copper nanoparticles.

Regina D Hadiwinata, Rui Zhang, Roman A Barmin, Fabian Kiessling, Twan Lammers, Roger M Pallares

Abstract readReview
In one paragraph

Review in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Regina D HadiwinataInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074, Aachen, Germany.
Rui ZhangInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074, Aachen, Germany.
Roman A BarminInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074, Aachen, Germany.
Fabian KiesslingInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074, Aachen, Germany.
Twan LammersInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074, Aachen, Germany.
Roger M PallaresInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074, Aachen, Germany. rmoltopallar@ukaachen.de.

Funding

Bundesministerium für Forschung, Technologie und Raumfahrt JPI Fellowship
6 · The paper itself

Abstract

Although the medical use of copper dates back millennia and medicines based on copper nanoparticles have been employed for over a century, their benefits are still often questioned. Over the past three decades, advances in nanotechnology have renewed interest in copper-based nanoformulations for healthcare. While most preclinical studies have focused on systemically administered copper nanomedicines for a broad range of therapeutic purposes, clinical trials remain scarce and are primarily centered on topical applications, where long-term off-target accumulation can be minimized to mitigate safety concerns. Despite exhibiting only moderate antiseptic activity compared with other inorganic nanomaterials, copper nanoparticles demonstrate significant wound healing potential through complex mechanisms involving angiogenesis promotion and stabilization of extracellular skin proteins. In this work, we discuss the current landscape of copper nanoparticles (and related microparticulate structures), and we thoroughly analyze the characteristics that have enabled their translation and use in clinical settings.

Indexed as

CopperMetal NanoparticlesAnimalsHumansTranslational Research, BiomedicalWound HealingCopperAntimicrobialClinical translationCopper nanoparticlesNanomedicineWound healing

Identifiers

PMID41795057
PMCPMC13619707

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.